natgillin/translations-raw huggingface dataset:
A further object of the present invention consists in the use of said compounds as medicaments, particularly for the preparation of pharmaceutical compositions useful for the treatment and prevention of psychotic, psychiatric and neurological disorders, particularly disorders related to increased activity of the mesolimbic dopaminergic pathway and/or to mesocortical dopaminergic hypofunctionality, such as, for example, schizophrenia in its positive and negative symptoms, paranoid states, manic-depressive states, disorders of the affective sphere, social regression, personality regression, and hallucinations. 
Daljnji predmet ovog izuma sastoji se u uporabi spomenutih spojeva kao lijekova, posebice za dobivanje farmaceutskih pripravaka korisnih za liječenje i prevenciju psihotičnih, psihijatrijskih i neuroloških poremećaja, posebice poremećaja povezanih s povišenom aktivnosti mezolimbčkih dopaminergičnih puteva i/ili mezokortičkom dopaminergijskom hipofunkcionalnošću, kao što su, na primjer, šizofrenija u svojim pozitivnim i negativnim simptomima, paranoidna stanja, manično-depresivna stanja, poremećaji afektivnog područja, socijalna regresija, osobna regresija, te halucinacije.
It is calculated to give approximately 10 mg/cm2 dry polymer per tablet surface area. 
Izračunata je da bi dala približno 10 mg/em" suhog polimera po površini tablete.
These Schemes 1 to 4 relate to the oxidation reaction I, the substitution reaction II, the substitution reaction III, and the nitrosation reaction IV, respectively. 
Te sheme 1 do 4 odnose se na reakciju I oksidacije, reakciju II supstitucije, reakciju III supstitucije i na reakciju IV nitrozacije.
a fourth software module executable by the processor and the memory, the fourth software module configured to copy the debugged portable executable file in memory to a storage medium; and a fifth software module executable by the processor and the memory, the fifth software module configured to terminate the debugging process at the original entry point. 
Sustav prema zahtjevu 9, naznačeno time da je četvrti softverski modul, konfiguriran za popravak (106) nevažećeg polja, konfiguriran za statistički popravak (116) nevažećeg polja uključujući: modificiranje (118) slike prijenosne izvršne datoteke na medij pohrane; i pohranu (120) modificirane slike na medij pohrane.
The method of any one of the preceding claims, wherein the rodent is a rat or a mouse. 
Glodavac iz zahtjeva 1., pri čemu je glodavac miš.
The composition for use according to claim 13, in the prevention or treatment in addition of intestinal disorders of the infant or of the child. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 14, naznačen time što je namijenjen sprječavanju ili liječenju i drugih crijevnih poremećaja kod dojenčeta ili kod djeteta.
Similarly, the invention provides the use of a second pharmaceutical agent in the manufacture of a medicament, wherein the medicament is for administration to a patient who has been pre-treated with IL-2 microaggregates of the invention. 
Slično, izum daje uporabu drugog farmaceutskog agensa u proizvodnji medikamenta, kod čega je medikament za davanje pacijentu koji se prethodno liječio s IL-2 mikroagregatima iz izuma.
A co-suspension according to any of claims 1 to 28 for use in a method for treating a patient suffering from an inflammatory or obstructive pulmonary disease or condition. 
Ko-suspenzija u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačena time što je namijenjena upotrebi u liječenje pacijenta koji boluje od upalne ili opstruktivne plućne bolesti ili stanja.
A method, according to claim 13, characterized in that said method comprises the step of making said electrically conductive pattern by a laminating operation and a following selective removing operation. 
Postupak u skladu s patentnim zahtjevom 13, naznačen time što se navedeni postupak sastoji u koraku pravljenja navedenog električno vodljivog uzorka radnjom laminiranja i naknadnom radnjom selektivnog uklanjanja.
Method according to any one of claims 1 to 3, characterised in that the AB-aggregates have a size of 50 nm to 15 µm, preferably from 100 nm to 10 µm, especially from 200 nm to 5 µm. 
Postupak prema bilo kojem od zahtjeva 1 do 3, naznačen time, da AB-agregati imaju veličinu od 50 nm do 15 um, poželjno od 100 nm do 10 um, posebno pogodno od 200 nm do 5 um.
The Compound according to Claim 9, for use in therapy in treating bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreas/gall bladder cancer, prostate cancer, thyroid cancer, osteosarcoma, rhabdomyosarcoma, MFH/fibrosarcoma, glioblastomas/astrocytomas, melanoma, or mesothelioma. 
Spoj prema zahtjevu 9, za uporabu u terapiji za liječenje raka mjehura, raka dojke, kolorektalnog raka, raka želuca, raka glave 1 vrata, raka bubrega, raka jetre, raka pluća, raka jajnika, raka gušterače/žučnog mjehura, raka prostate, raka štitnjače, osteosarkoma, rabdomiosarkoma, MFH/fibrosarkoma, glioblastoma/astrocitoma, melanoma ili mezotelioma.
According to any embodiment of the methods disclosed herein, the daily 24-hour Local Injection Site Reaction (LISR) score is reduced relative to the daily 24-hour LISR score associated with subcutaneous injection of 1.0 ml of an aqueous pharmaceutical solution of 20 mg glatiramer acetate and 40 mg mannitol. 
Jedinična doza prema jednom od patentnih zahtjeva 1-13, naznačena time, da nakon supkutane injekcije uzrokuje smanjenu dnevnu vrijednost lokalne reakcije na mjestu uboda (LISR) nakon 24 sata, u odnosu na dnevnu vrijednost lokalne reakcije na mjestu uboda (LISR) nakon 24-sata, povezane sa supkutanom injekcijom od 1,0 ml vodene farmaceutske otopine od 20 mg glatiramer acetata 1 40 mg manitola.
(2001) Molecular Pharmacology 59:349-357 and reviewed therein]. 
(2001) Molecular Pharmacology 59:349-357].
The system of claim 1, wherein the distal port (115) is extendable from a channel (116) in the introducer (102) a distance of 5 to 10 mm. 
Sustav prema zahtjevu 1, naznačen time da se distalni dio (115) može produljiti od kanala (116) u uvodniku (102) na udaljenost 5 do 10 mm.
Advantageously, the conversion of said organic material may according to another aspect of the present invention be at least 90%, such as at least 95%, and preferably above 97.5% %, such as above 99%, and even more preferably above 99.5%, such as above 99.9%. 
Metoda u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu je pretvorba navedenog organskog materijala najmanje 90 %, kao što je najmanje 95 %, a poželjno iznad 97.5 %, kao što je iznad 99 %, a još poželjnije iznad 99,5 %, kao što je iznad 99.9 %.
The method according to any one of the preceding claims, wherein the number of oil droplets having a size > 1.2 µm in the first emulsion is 5 x 1011 /ml or less. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da je broj kapljica ulja veličine > 1.2 um u prvoj emulziji 5 x 10' /mlili manji.
The antibody, for use according to claim 9 or the pharmaceutical composition for use according to claim 10, wherein said haematological disease is taken from the list of multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia and acute lymphocytic leukemia or wherein said inflammatory disease is taken from the list of rheumatoid arthritis and systemic lupus erythematosus. 
Antitijelo, za upotrebu prema patentnom zahtjevu 7 ili farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 8, naznačena time što je navedena hematološka bolest izabrana s liste na kojoj se nalaze multipli mijelom, kronična limfocitna leukemija, kronična mijeloidna leukemija, akutna mijeloidna leukemija i akutna limfocitna leukemija.
The high protein, acidified dairy product according to claim 8 or 9, having a total amount of CMP of at least 5% (w/w) relative to the total amount of protein, preferably at least 10% (w/w), and even more preferably at least 12% (w/w) relative to the total amount of protein. 
Visokoprotetnski, zakiseljeni mliječni proizvod u skladu s patentnim zahtjevom 8 ili 9, naznačen time što ima ukupnu količinu CMP od najmanje 5 % (tež./tež.) u odnosu na ukupnu količinu proteina, po mogućnosti najmanje 10 % (tež./tež.), a još poželjnije najmanje 12 % (tež./tež.) u odnosu na ukupnu količinu proteina.
Rb and Rc are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or said Rb and Rc together with the N to which they are bonded optionally form a heterocycle or substituted heterocycle; 
Rb i Rc su nezavisno vodik, alkil ili supstituirani alkil, cikloalkil ili supstituirani cikloalkil, heterocikl ili supstituirani heterocikl, ili aril ili supstituirani aril, ili ti Rb i Rc zajedno s N s kojim su spojeni po izboru formiraju heterocikl ili supstituirani heterocikl; i n je 1-4;
An example of such acid is phosphoric acid or sulfuric acid. The at least one water-soluble acid provided in step b) is dosed in a molar amount relative to the numbers of moles of the calcium carbonate containing mineral in the range from 0.01 mol/mol to about 1 mol/mol. 
Postupak prema jednom od zahtjeva 1 do 7, naznačen time da se barem jedna kiselina koja se otapa u vodi dozira u molarnoj količini u odnosu na broj molova kalcijevog karbonata koji sadrži mineral u rasponu od 0.01 mol/mol do oko 1 mol/mol, poželjno od 0.1 do 0.6 mol/mol.
Retain for addition in later step. 
Odgoditi dodavanje za slijedeći korak.
The term “extraction” and “extraction module” has been used as it is usually used when referring to the production of a coffee beverage. 
Izraz "ekstrakcija" 1 "modul za ekstrakciju" sa koriste kao što se to 1 obično koristi kada se radi o proizvodnji napitka od kave.
An ophthalmic combination comprising 
Oftalmička kombinacija sadrži i)
is a hydrogen atom, hydroxy, C1-6 alkyl which may be substituted with a hydroxy, C1-6 alkoxy which may be substituted with C1-6 alkoxy, or C1-6 alkylcarbonyl. is preferably: 
R; je atom vodika, hidroksi, C,g alkil koji može biti supstituiran sa hidroksijem, C,.g alkoksi koji može biti supstituiran sa C1.g alkoksijem, ili Cy.4 alkilkarbonil, ili njihova sol.
Meanwhile, in FIG. 13, the sub LNG supply line L24 is illustrated as being branched from the main LNG supply line L23 at the upstream side of the high pressure pump 43. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 2, naznačen time što se pomoćna linija za slanje LNG (1.24) grana od glavne linija za slanje LNG (L23) na uzvodnoj strani visokotlačne crpke (43).
The aqueous pharmaceutical suspension according to claim 7, wherein the butylparaben, or sodium butylparaben is, by weight/volume (g/100 mL), about 0.014% to about 0.020%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što butilparaben ili natrij- butilparaben iznosi, težinski/volumno (£/100 ml), otprilike 0,014 % do otprilike 0,020 %.
A Turkish coffee machine (1) comprising 
PATENTNI ZAHTJEVI Aparat za tursku kavu (1) koji obuhvaća
It is also possible to reconstitute a lyophilised cake with an aqueous composition comprising human serum albumin (preferably recombinant). 
Također je moguće rekonstituirati liofilizirani kolač s vodenim sastavom koji sadrži humani serum albumin (pogodno rekombinantni).
the therapeutic antibody, 
terapijskog protutijela
wherein R7, R8, R11, R12, R13 and R15 are as defined for formula (II). 
pri čemu su R7, R8, R11, R12, R13 i R15 kao što su definirani za formulu (I).
An antibody which binds to AXL (SEQ ID NO: 130) and comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 36, 37, and 38, respectively, and the VL region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO: 39, GAS, and SEQ ID NO: 40, respectively. 
VH područje koje obuhvaća SEQ ID br. 29 i VL područje koje obuhvaća SEQ ID br. 30 [620-06]. Protutijelo prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, da navedeno najmanje jedno područje vezanja obuhvaća VH područje koje obuhvaća sekvence CDR1, CDR2 i CDR3 od SEQ ID br. 36, 37, odnosno 38; i VL područje koje obuhvaća sekvence CDR1, CDR2 i CDR3 od SEQ ID br. 39, GAS, odnosno 40 [107].
A further aspect of the invention are novel thiazolidin-4-one derivatives of the following General Formula (II): 
Novi derivati tiazolidin-4-ona Opće formule (II) t>& HR P20100714 TI R* R2!
The interior of the housing includes one or more cam surfaces that, on movement of the jar mandrel upwardly in the housing, engage the latch keys. 
Unutrašnjost kućišta sadrži jednu ili više nazubljenih površina koje zahvaćaju elemente zasuna prilikom kretanja vretena udaraca u kućištu prema gore.
A drive roller, comprising: 
Pogonski valjak (1, 18) koji obuhvaća
The method of claim 1 wherein the disorder is selected from the group consisting of pulmonary disorders, inflammatory diseases, and functional bowel disorders. The method of claim 11 wherein the pulmonary disorder is selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. 
Spoj ili sol prema bilo kojem od zahtjeva 1 do 9 ili farmaceutski sastav prema zahtjevu 11, naznačen/a time, da je za uporabu u postupku liječenja astme, kronične opstrukcijske plućne bolesti (COPD), upalne bolesti crijeva ili cistične fibroze.
a sensor device (558) arranged outside the successive phase contact devices for determining a parameter of the solid phase as it moves along the pathway. 
(b) senzorski uređaj (558) raspoređen izvan sukcesivnih faznokontaktnih uređaja za određivanje parametra čvrste faze dok se pomjera duž putanje.
DHFR enzyme was purified from rat livers or the commercially available DHFR was used, this being produced by recombinant expression in E. coli . 
DHFR enzim je pročišćen iz jetra štakora ili je upotrijebljen komercijalno dostupan DHFR koji se proizvodi rekombinantnom ekspresijom u E. coli.
Method according to any of claims 1 to 12, wherein the cocoa beans of step c) have an amount of components selected from the group comprising aroma compounds, aroma precursor, ester-precursors, free amino acid precursors, aromatic bioactive molecules, alkaloid compounds, sugars, carbohydrates, and enzymes which is at least 10 % higher or at least 10 % lower than the amount in the cocoa beans of step a). 
Postupak prema bilo kojem zahtjevu 1 do 12, naznačen time, da kakao zrna iz koraka c) imaju količinu sastojaka odabranih iz skupine koja sadrži aromatske spojeve, aromatske predkursore, ester-predkursore, slobodne amino kiselinske predkursore, aromatske bioaktivne molekule, alkaloidne spojeve, šećere, ugljikohidrate i enzime, koja je najmanje 10% veća ili najmanje 10% manja od količine kakao zrna iz koraka a).
Some implements use mechanical conveyors. 
Neki uređaji koriste mehaničke transportere.
cooling the G-CSF composition provided in step (a) to a temperature of −15° C. or lower to obtain a frozen G-CSF composition; 
(b) hlađenje G-CSF-sastava pribavljenog u koraku (a) do temperature od -I5C ili ispod toga za dobivanje zamrznute G-CSF-formulacije;
an antibody having a heavy chain as shown in SEQ ID NO: 27 and a light chain as shown in SEQ ID NO: 28; 
(ili) antitijelom koje ima teški lanac kao što je prikazano u SEK ID BR: 27 i laki lanac kao što je prikazano u SEK ID BR: 28;
Stirring at +4°C is continued for an hour, then DIPEA (2 eq) and Boc-piperazine (1 eq) are added and the mixture is left to warm to room temperature, under stirring. 
Miješanje pri +4T je nastavljeno jedan sat te su dodani DIPEA (2 ekviv.) i Boc-piperazin (1 ekviv.) i smjesa je ostavljena da se ugrije do sobne temperature uz miješanje.
Main XRPD peaks for Compound (1) Lactate salt - form FL3 
Kombinacija koja sadrži kiselinsku adicijsku sol spoja formule (1) o
reacting a compound of Formula IIIc: a reagent of formula R1MgY, followed by reacting with a compound of formula B(OR2)3 to form a compound of Formula IIId: and 
X llc reagensa s formulom R,MgY, nakon čega slijedi reakcija sa spojem s formulom B(OR>); da se dobije spoj s formulom IIId: m
A candle holder (10) in accordance with any one of clauses 1 to 8 wherein the candle holder (10) comprises a lip (18) extending transversely away from the candle holder (10). 
Aranžman sa svijećnjakom sukladno bilo kojem od Zahtjeval do 7 pri čemu svijećnjak (10) sadrži usnicu (18) koja se transverzalno pruža od svijećnjaka (10).
average diameter of 50% of the microcapsules: 
Broj objave europskog patenta:
The method of claim 1 wherein the first set of components comprises less than 5 wt % fused AZS particles. 
Metoda iz bilo kojeg od patentnih zahtjeva 1-3, pri čemu prvi set komponenata obuhvaća manje od 5 wt% fuzioniranih AZS čestica.
The controlled release formulation of claim 1, wherein the (PLG) copolymer material has a weight average molecular weight of about 15 kilodaltons to about 50 kilodaltons and a polydispersity index from about 1.4-1.8. 
PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja iz patentnog zahtjeva 1, gdje uklonjena kopolimerna frakcija je oko 3% do oko 15% po masi od zbira masa uklonjene kopolimerne frakcije i PLG kopolimernog materijala sa smanjenim efektom naglog oslobađanja.
A method of randomly linking a plurality non-contiguous nucleotide sequences of interest, wherein said nucleotide sequences of interest comprise variable region encoding sequences and the linkage generates a combinatorial library of pairs of variable region encoding sequences, preferably wherein said nucleotide sequences of interest comprise immunoglobulin variable region encoding sequences and the linkage generates a combinatorial library of pairs of light chain variable region and heavy chain variable region encoding sequences, said method comprising: 
Postupak nasumičnog spajanja više nesusjednih nukleotidnih sljedova od interesa, gdje navedeni nukleotidni sljedovi od interesa uključuju sljedove koji kodiraju varijabilno područje, gdje se spajanjem dobije kombinatorijska biblioteka parova sljedova koji kodiraju varijabilno područje, gdje po mogućnosti navedeni nukleotidni sljedovi od interesa uključuju sljedove koji kodiraju varijabilno područje imunoglobulina, gdje se spajanjem dobije kombinatorijska biblioteka parova sljedova koji kodiraju varijabilno područje lakog lanca i varijabilno područje teškog lanca, naznačen time što se navedeni postupak sastoji u:
The preferred buffer systems can be the complex of salts for the phosphate and citrate buffer, preferably in the form of sodium or potassium salts. 
sol klorovodične, octene, sumporne, trifluoroctene, metansulfonske, jantarne ili etilendiaminotetraoctene kiseline, preferirano u obliku bis-hidrokidnog klorida (MEN16132).
The catalyst solution was then transferred to the hydrogenator under nitrogen. 
Otopina katalizatora je zatim prebačena u hidrogenator pod dušikom.
a light chain variable domain having all three CDRs of the variable domain of SEQ ID NO: 2. 
drugu varijabilne domene (koja se ovdje također definira "varijabilna domena laganog lanca") koja je definirana slijedećom sekvencom:
A method of preparing a composition according to claim 33, the method comprising admixing said inhibitor of dipeptidyl peptidase IV (DPP-IV), said compound, and said pharmaceutically acceptable carrier. A composition according to claim 1, wherein: the compound is selected from the following compound and pharmaceutically acceptable salts, solvates, and hydrates thereof: 
Postupak izrade pripravka u skladu sa zahtjevom 33, naznačen time, da postupak obuhvaća miješanje navedenog inhibitora dipeptidil peptidaze IV (DPP-IV), navedenog spoja i navedene farmaceutski prihvatljive podloge. . Pripravak u skladu sa zahtjevom 1, naznačen time, da: spoj je izabran među slijedećim spojem i njegovim farmaceutski prihvatljivim solima, solvatima i hidratima:
Preparation of Compound #1 of the present invention 
Broj objave europskog patenta:
The same happens when a person contacts the “hot” wire while touching or standing on a conductive surface to ground. 
Isto se može dogoditi ako osoba dođe u kontakt s fazom dok dodiruje ili stoji na vodljivoj površini prema zemlji.
The method according to claim 1, wherein adjusting the speed and/or the torque comprises comparing the measured tension value of the yarn with the reference tension value and determining a value of speed and/or torque to impart onto the bobbin. 
gdje se korak podešavanja brzine i/ili zakretnog momenta kalema (2) sastoji u koracima uspoređivanja izmjerene vrijednosti napetosti niti (F) s referentnom vrijednosti napetosti i određivanja navedene vrijednosti brzine i/ili zakretnog momenta koje treba prenijeti na navedeni kalem (2).
The isolated mouse cell of claim 1, wherein an endogenous mouse λ light chain locus is deleted in whole or in part. 
Mišja stanica prema zahtjevu 6, naznačena time, što endogeni lokus imunoglobulina lakog lanca A sadrži endogeni mišji pojačivač 2.4 ili endogeni mišji 3' pojačivač.
a step of producing the compound of the formula (7) from the compound of the formula (7a): (in the formula, Lv represents leaving group, Me represents methyl, iPr represents isopropyl, and R represents isopropyl or (2R)-2-fluoropropyl); 
(7a) (7) (u formuli Lv predstavlja izlaznu skupinu, Me predstavlja metil, iPr predstavlja izopropil, a R predstavlja izopropil ili (2R)-2-fluorpropil);
The variables in the schemes are meant only to illustrate how to make some of the compounds of this invention. 
Varijable u shemama su namijenjene samo da ilustriraju kako napraviti neke od spojeve prema ovom izumu.,,X" i,n" obuhvaćaju alkilen razdvajače koji mogu sadržavati 15
Cancer Res., 2001, 7, 1850) as well as other cancers of the lung (Hendler et al., Cancer Cells, 1989, 7, 347; Ohsaki et al., Oncol, Rep., 2000, 7, 603), bladder cancer (Neal et al., Lancet, 1985, 366; Chow et al., Clin. 
Cancer Res., 2001, 7, 1850) kao i ostalim plućnim tumorima (Hendler i sur., Cancer Cells, 1989, 7, 347; Ohsaki i sur., Oncol. Rep., 2000, 7, 603), raku mjehura (Neal i sur., Lancet, 1985, 366; Chow i sur., Clin.
is selected from optionally substituted heteroaryl having 5 to 15 ring atoms and optionally substituted aryl having 6 to 12 ring atoms, wherein the optional substituents on R2 groups are 1, 2 or 3 substituents independently selected from halogen, C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, C1-C4 thioalkoxy, hydroxyl, amino, C1-C4 alkylamino, C1-C4 dialkylamino, sulfhydryl, cyano, C6 aryl and heteroaryl having 5 or 6 ring atoms. 
R* je odabran od po izboru supstituiranog heteroarila koji ima 5 do 15 atoma u prstenu i po izboru supstituiranog arila koji ima 6 do 12 atoma u prstenu, pri čemu su proizvoljni supstituenti na R* skupinama 1, 2 ili 3 supstituenta neovisno odabrani iz niza koji čine halogen, Ci-Cu alkil, halo-C,-C, alkil, C,-Cy alkoksi, C;-C, tioalkoksi, hidroksil, amino, C,-C, alkilamino, C;- Cu dialkilamino, sulfhidril, cijano, Cg aril i heteroaril koji ima 5 ili 6 atoma u prstenu.
the compound of formula (VIII) is subjected to an alkylation reaction in the presence of a base and of a halogenated derivative Ra'X, Ra' being as defined in Claim 1 and X being a halogen. 
spoj s formulom (VIII) se podvrgava reakciji alkilacije u prisutnosti baze i halogeniranog derivata Ra'X, te je Ra' kako je definirano u zahtjevu 1 i X je halogen.
The composition according to claim 6, wherein the buffer is histidine, wherein the concentration of histidine is preferably 20 mM, wherein the pH is preferably in the range 5-7, and wherein the pH is most preferably in the range 5.5-6. 
Pripravak u skladu s patentnim zahtjevom 6, pri čemu je pufer histidin, pri čemu je koncentracija histidina poželjno 20 mM, pri čemu je pH vrijednost poželjno u rasponu 5-7 i pri čemu je pH najpoželjnije u rasponu 5.5 – 6.